Publicaciones científicas

Adjuvants for allergy immunotherapeutics

Gamazo C (1), D Amelio C (2), Gastaminza G (3), Ferrer M (4), Irache JM (5). (1a) Dept. Microbiology, Instituto de Investigación Sanitaria de Navarra (Idisna), University of Navarra - C/Irunlarrea, 1; 31080 - Pamplona, Spain
(2b) Department of Allergology and Clinical Immunology, Clínica Universidad de Navarra - address: Av. Pio XII 36, 31008-Pamplona-Spain.
(3c) Department of Allergology and Clinical Immunology, Clínica Universidad de Navarra - address: Av. Pio XII 36, 31008-Pamplona-Spain.
(4d) Department of Allergology and Clinical Immunology, Clínica Universidad de Navarra - address: Av. Pio XII 36, 31008-Pamplona-Spain.
(5e) University of Navarra , Dept. Pharmacy and Pharmaceutical Technology; C/Irunlarrea, 1; 31080 - Pamplona, Spain.

Revista: Human Vaccines & Immunotherapeutics

Fecha: 21-ago-2017

Alergología e Inmunología Clínica

RESUMEN

Allergic diseases are reaching epidemic proportions in developed countries. In particular, food allergy is increasing in prevalence and severity, thus becoming an important socioeconomic burden. Numerous cell types and cell populations, which form an intricate and balanced network, are involved in an immune response.

This balance is occasionally disturbed, leading to the onset of different diseases, such as allergic diseases. Antihistamines and corticosteroids provide some degree of relief from the symptoms of allergic conditions. However, the only treatment that can revert the disease is immunotherapy. Nevertheless, specific immunotherapy has at least two major drawbacks: it is time-consuming, and it can produce local and even systemic allergic side effects. Immunotherapy's potential goes beyond our current knowledge of the immune response; nevertheless, we can still design strategies to reach a safer immune modulation for treating allergies.

This review deals with the use of adjuvants to reduce the undesirable side effects associated with specific allergen immunotherapy. For example, nanoparticles used as immunoadjuvants are offering promising results in preclinical assays.

CITA DEL ARTÍCULO  Hum Vaccin Immunother. 2017 Aug 21:0. doi: 10.1080/21645515.2017.1348447

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra